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Range verification methods in
particle therapy: underlying physics
and Monte Carlo modeling
Aafke Christine Kraan*
Department of Physics, National Institute for Nuclear Physics (INFN), University of Pisa, Pisa, Italy
Hadron therapy allows for highly conformal dose distributions and better sparing of
organs-at-risk, thanks to the characteristic dose deposition as function of depth. How-
ever, the quality of hadron therapy treatments is closely connected with the ability to
predict and achieve a given beam range in the patient. Currently, uncertainties in particle
range lead to the employment of safety margins, at the expense of treatment quality.
Much research in particle therapy is therefore aimed at developing methods to verify
the particle range in patients. Non-invasive in vivo monitoring of the particle range can
be performed by detecting secondary radiation, emitted from the patient as a result
of nuclear interactions of charged hadrons with tissue, including + emitters, prompt
photons, and charged fragments. The correctness of the dose delivery can be verified
by comparing measured and pre-calculated distributions of the secondary particles. The
reliability of Monte Carlo (MC) predictions is a key issue. Correctly modeling the production
of secondaries is a non-trivial task, because it involves nuclear physics interactions at
energies, where no rigorous theories exist to describe them. The goal of this review is to
provide a comprehensive overview of various aspects in modeling the physics processes
for range verification with secondary particles produced in proton, carbon, and heavier ion
irradiation. We discuss electromagnetic and nuclear interactions of charged hadrons in
matter, which is followed by a summary of some widely used MC codes in hadron therapy.
Then, we describe selected examples of how these codes have been validated and
used in three range verification techniques: PET, prompt gamma, and charged particle
detection. We include research studies and clinically applied methods. For each of the
techniques, we point out advantages and disadvantages, as well as clinical challenges
still to be addressed, focusing on MC simulation aspects.
Keywords: hadron interactions, Monte Carlo modeling, range verification, PET, prompt gamma
1. Introduction
The main challenge in radiotherapy for cancer treatment is how to deliver high dose to the tumor
region, whileminimizing the irradiation of healthy tissue. One of themost important newmodalities
being developed for cancer therapy is irradiationwith charged ions. Thanks to the characteristic dose
deposition profile (Bragg peak), charged particles offer the possibility to deposit dose much more
locally than the photons, so dose in healthy tissue can be minimized (1, 2). However, treatments
with charged particles are more sensitive to uncertainties than photon treatments, because of their
steep dose profile. Error sources include anatomical changes (e.g., organ motion, tumor regression,
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weight loss), patient setup errors and range errors from uncertain-
ties in CT Hounsfield units (HU), conversion of HU into particle
stopping power, and reconstruction artifacts (3). These can result
in under-dosage to the tumor and unwanted dose to healthy
tissue. Because of these uncertainties, in particle therapy clinics,
generally large safety margins around the tumor are employed,
and/or probabilistic or robustly optimized conservative treatment
plans are used. This may not be optimal for the patient and may
impair the beneficial effects of charged particle therapy. Much
research in particle therapy is therefore aimed at developing new
methods, which enable to verify the particle range in patients.
Various techniques for particle range verification have been
developed over the last decades (4). Non-invasive in vivo treat-
ment monitoring can be performed by detecting secondary par-
ticles produced as a result of nuclear interactions of the incident
particle beam with the patient tissue, like + emitters, prompt
photons, and charged fragments. Monte Carlo (MC) simulations
have played a crucial role in the development and clinical applica-
tion of range verification techniques. They can accurately describe
particle transport and interactions of radiation with matter in
complex geometries, such as fully detailed CT descriptions of the
patient anatomy. This makes them a suitable tool for feasibility
and detector design studies. Furthermore, in vivo non-invasive
range monitoring methods generally rely on direct comparisons
between measured and MC predicted distributions of secondary
particles. The accuracy of theMC codes is therefore a crucial issue.
Unfortunately, modeling nuclear interactions and the resulting
secondary particle production is a highly complex task, because
it involves nuclear physics interactions, for which no rigorous
models exist.
Althoughmuch literature is available on interactions of charged
particles inmatter, reviews dedicated to particle therapy are scarce
and nuclear interactions are often only discussed superficially.
For instance, a dedicated review about interactions of charged
particles in radiation therapy is written by Lomax (5), but it only
very briefly touches on nuclear interactions. Moreover, it does
not include range verification methods and MC models. The
same applies to valuable reviews about physics of heavy charged
particles (6, 7). Also, Gottschalk has written an excellent summary
about proton interactions, including some nuclear physics (8),
but it does not include MC codes and in vivo range verifica-
tion. Very recently, a valuable review written by Newhauser and
Zhang (9) about proton physics was published, including Monte
Carlo and analytical modeling of proton interactions; however,
nuclear interactions are discussed shortly and range verification
techniques were not reviewed. And vice versa, thorough reviews
about range verification methods are available (4), but the physics
interactions andMCcodesmodeling themare described only very
shortly. Extensive reviews exist about the usage of MC techniques
in particle therapy (10, 11), but these do not contain a systematic
description of interactions of charged hadrons in matter. Further-
more, the number of particle treatment centers around the world
is growing, and thereby the demand for in vivo non-invasive range
verification methods increases. In view of the rapidly evolving
technical developments in the last years, we believe that an up-to-
date description of the different range verification strategies, the
state-of-the-artMC codes, and their underlying physics principles
is timely.
This review intends to give a comprehensive overview of vari-
ous aspects in modeling the physics processes that are relevant in
range verification methods based on secondary particle detection
in proton, carbon, and heavier ion irradiation. We will cover the
physics principles behind the various range verification methods,
the MC codes to simulate them, and the validation of the codes,
including both clinically implementedmethods as well as research
studies. Hereby, we highlight the difficulties, limitations, and
challenges related to physics modeling for range monitoring. This
review is organized in the following way:
Section 2 is devoted to a brief description of interactions of
charged particles inmatter for energy ranges relevant in radiother-
apy. We discuss both electromagnetic and nuclear interactions,
and point out some practical consequences regarding beam flu-
ence and dose. Moreover, we discuss some general approaches
in modeling nuclear interactions, adopted by most state-of-the-
art MC codes used in hadron therapy, and show how nuclear
interactions give rise to production of + emitters, prompt ’s,
and charged fragments.
Range verification methods rely heavily on the accuracy of
the particle transport code for describing dose deposition and
nuclear fragmentation. Section 3 presents a summary of the avail-
able MC codes that are most widely used in particle therapy,
and in particular in research related to particle range verifica-
tion. For each MC generator, we briefly discuss how the rele-
vant physics processes are modeled, and we give some examples
of how these models are validated for proton and heavy ion
therapy.
In Section 4, we review the use of MC codes in non-invasive
particle range verification, focusing on three techniques: PET,
prompt , and charged particle imaging. For each strategy, we
describe selected examples of the application of the codes to
treatment monitoring, as well as the available detectors. We also
highlight some remaining clinical challenges regarding physics
modeling.
In Section 5, we compare the three techniques, pointing out
their strength and drawbacks. We also briefly touch on the devel-
opment of hybrid systems. Finally, we describe some common
efforts, which could improve the accuracy of signal prediction in
treatment monitoring techniques.
2. Interactions of Charged Particles
in Matter
In this section, we review electromagnetic and nuclear interac-
tions of charged ions in matter. We narrow our focus to parti-
cle types and energies currently used in particle therapy centers
worldwide. This means that we consider interactions of protons
up to about 250MeV and carbon ions up to about 450MeV/u,
i.e., penetrating into the human body up to about 40 cm. Before
going into detail, let’s first quickly look at their typical velocities.
For a particle of kinetic energy Ekin, total energy Etot, massm0, and
momentum p, the particle velocity in units of the velocity of light
c is given by:
  v
c
=
pc
Etot
=
p
E2tot  m20c4
Ekin +m0c2
=
q
E2kin + 2Ekinm0c
2
Ekin +m0c2
(1)
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For a proton with kinetic energy Ekin = 250MeV and given the
proton mass= 938MeV/c2, we find  0.6, while a carbon ion
with energy 450MeV/u has  0.7. Thus, in radiotherapy, we
generally deal with moderately relativistic particles.
2.1. Electromagnetic Interactions
2.1.1. Electromagnetic Energy Losses for Charged
Particles
Moderately relativistic charged particles interact with material by
electrical (Coulomb) forces with the atomic electrons andwith the
material nuclei. The particle looses energy primarily by inelastic
collisions with the atomic electrons, resulting in ionization and
atomic excitation. These are continuous energy losses. When the
ejected electron is so energetic that it can cause ionization itself,
we call it a delta-ray. The amount of energy lost due to Coulomb
interactions with the material nuclei is very small (12).
For charged particles other than electrons with charge number
Zp moving in a target material of atomic number Zt and density
 with velocity  larger than the orbital electron velocity, the
mean ionization energy loss (or electronic stopping power) can
be described by the Bethe-Bloch equation (12–14):
dE
dx
= K
Z2p
2
Zt
At

1
2
ln

2mec222Tmax
I2e

  2   
2
  C
Zt

(2)
with K = 4NAr2emec2, NA Avogadro’s number, re and me are
the radius and mass of the electron, At the molar mass of the
material,  = 1p
1 1=2 , Ie is the mean ionization potential of
the material. Furthermore,  is the density correction, relevant
only for ultra-relativistic charged particles, and C is a shell cor-
rection term, which becomes important when the particle velocity
becomes closer to the velocity of the atomic electrons. Heavy ions,
which are fully stripped at high velocities, get partly neutralized
by picking up electrons from the target material as they slow
down. This decreases the particles’ effective charge (Zp)eff that
has to replace Zp in Eq. 2. The latter represents only the main
contributions to the stopping power. There exist several higher-
order corrections in Zp, which have been proposed to improve Eq.
2, like Barkas, Bloch, and Mott corrections. For a more extensive
discussion, we refer to a comprehensive review by Ziegler (12).
The ionization potential can be parameterized for instance in
Ref. (15):
Ie(Zt) = (12Zt + 7) eV for Zt  13 (3)
Ie(Zt) = (9:76Zt + 58:8Z
 0:19
t ) eV for Zt > 13 (4)
Here, Tmax is the maximum kinetic energy, which can be trans-
ferred to a free electron in a single collision and is given, for an
incident particle of massM, in Ref. (14):
Tmax =
2mec222
1 + 2me=M + (me=M)
2
(5)
For very low energies, when  becomes comparable or less
than the velocity of the orbital electrons, the so-called Lindhard
region, Eq. 2, is no longer valid. Then, the energy loss becomes
proportional to  (16) and is of the order of:
dE
dx
= 8NA
At
~2
me
Z
7=6
p Zt
Z

o
; (6)
where Z
2
3 = Z
2
3p + Z
2
3
t and o = e
2
4"0~c (0.0073) are
the electron velocity in the classical lowest Bohr orbit of the
hydrogen atom. In between the Bethe-Bloch and the Lindhard
region, energy losses can be described by the low energy model
of Anderson and Ziegler (17); alternatively, a polynomial can be
used to join up the regions. For compoundmaterials, the stopping
power is the weighted sum of all the single elements, corrected for
ionization energy.
The electronic stopping power as function of the kinetic energy
of protons impinging on a water target is shown in Figure 1,
where the various regions mentioned above are indicated. Also
indicated is the nuclear stopping power resulting from Coulomb
interactions of the incident particles with the atomic nuclei, which
is seen to contribute very little to the total stopping power. In
Figure 2, the energy loss as function of depth is given for protons
(left) and 12C ions (right) for various energies. The growing energy
losswith decreasing particle velocity described by the Bethe-Bloch
formula causes the characteristic Bragg peak.
The range R of a particle beam is the depth in the medium, at
which half of the particles undergoing electromagnetic interac-
tions have stopped. In practice, a dosemeasurement is used, where
the range is defined as the distal 80% point of the Bragg peak (8).
The Bragg-peak is never perfectly sharp. First of all, the ion-
ization energy loss of a charged particle traversing a medium
is a stochastic process, so that the actual range of each single
particle deviates from the expected mean value. This longitudinal
widening of the Bragg peak is known as range straggling. Second,
the beam is never perfectly mono-energetic. Depending on the
machine, the spread is of the order of 1% of the energy (5).
Continuous ionization energy losses of charge particles are typ-
ically modeled in Monte Carlo codes analytically down to about
2MeV, based on a continuous-slow-down-approach (CSDA)
building on the Bethe-Bloch equation, but including relevant
FIGURE 1 | Stopping power (dE/dx), in MeVcm2 g 1, for protons in
water as function of kinetic energy. The total, electronic, and nuclear
stopping power are shown, as well as the characteristic regions. Made using
NIST data (18).
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FIGURE 2 | Left: stopping power of protons with various energies in MeV, showing CNAO data and FLUKA simulations. Adapted from Ref. (19), with permission.
Right: stopping power of carbon ions with various energies including data and Geant4 simulations. Reproduced from Ref. (20), with permission.
correction factors in Zp. Below 2MeV parameterizations are usu-
ally used. Energy straggling is partly taken into account by the
emission of delta-rays, and it can be modeled using a statistical
approach to include fluctuations, for instance, based on Gaussian
fluctuations or the Landau or Vavilov theories (13).
2.1.2. Multiple Coulomb Scattering
Besides inelastic collisions with the atomic electrons, a charged
particle also suffers numerous elastic Coulomb scatterings from
the nuclei themselves. The energy loss as a result of multiple
Coulomb scattering (MCS) is negligible, but it is nevertheless
important for dosimetry, because it causes lateral broadening of
the pencil beam. Theoretical calculations of the scattering angle
are highly complex.One of themost complete derivationswas per-
formed byMolière (21), and various calculations in order to derive
more practical formulas were performed afterwards, for instance
byLewis (22),Highland (23), andGottschalk (24).Due to theCen-
tral Limit Theorem, the probability distribution of the net angle of
deflection of a particle in a thick material is very nearly Gaussian,
resulting from the sum of many small random deflections. An
approximation for the probability distribution for the net angle
of deflection by MCS in a material was derived by Highland (23),
and can be approximated by a Gaussian distribution with a width
given by:
0 =
14:1MeV
cp
Zp
p
L=L0[1 + 0:038ln(L=L0)] (7)
where L the thickness of the scattering material and L0 the radi-
ation length. The gaussian description is not perfect, and the
presence of large-angle tails, which are the result of single scatters
in the target, are not quite negligible and are typically simulated in
MC codes. Also, for heavy particles, nuclear form factors should
be applied, as well as Fano corrections (13). Figure 3 shows the
lateral beam widening for proton and carbon projectiles.
Multiple Coulomb scattering is generally modeled in Monte
Carlo codes through a combination of “condensed” MC simula-
tionsmethods (most frequently based onMolière or Lewis theory,
the latter also allowing to predict moments of lateral displace-
ment) and the possibility for single large-angle scatterings. While
in the former method, only the net displacement, energy loss, and
change of direction at the end of the particle track are calculated,
the latter allows simulating discrete single scatterings.
FIGURE 3 | Lateral scattering (FWHM – full width at half maximum) as
function of distance from the beam exit window for various proton
and carbon energies, calculated for a nozzle based on the GSI therapy
facility. The beam enters the patient body at a distance of 1.40m from the
exit. Reproduced from Ref. (25), with permission.
2.2. Nuclear Interactions
Charged particles can also suffer nuclear interactions with the
material nuclei. These interactions contribute significantly less to
energy losses than electromagnetic processes. Still, they are highly
relevant for range verificationmethods, as we will see below. Con-
trary to electromagnetic interactions, no rigorous models exist to
describe them. In the following, we briefly describe the common
approaches to model nuclear interactions, as adopted by most
state-of-the-art MC codes.
2.2.1. General Aspects
In most MC codes, nuclear interactions are handled in two sep-
arate steps. First, the probability that a nuclear event happens is
sampled, based on nuclear cross sections. Depending on the inci-
dent particle and energy, these can be calculated “on-the-fly,” i.e.,
on an event-by-event basis using for instance parameterized for-
mulas and/or physics models, or by “looking-up” a pre-evaluated
cross section from a nuclear database. Examples of large nuclear
databases are the Evaluated Nuclear Data File (ENDF) (26), the
Japanese Evaluated Nuclear Data Libraries (JENDL) (27), and the
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Exchange Format (EXFOR) database (28). These contain data of
thousands of experiments stored in a given format, which can be
accessed from all over the world.
Once an event happens, the outcomemust be sampled. This can
be done with appropriate nuclear interaction models, or by using
information on spectra and angular distributions from evaluated
nuclear databases. As we will see in Section 3, different trans-
port codes use data libraries in different energy regions, and for
reactions induced by different projectiles.
Nuclear interactions (collisions) can be divided into:
 Elastic collisions: here kinetic energy is conserved, and the
nucleus stays intact. This is similar to multiple Coulomb scat-
tering, but now due to strong rather than electromagnetic inter-
actions. Such interactions are not occurring so frequently, but
still they cause a certain amount of broadening of the beam,
which is simulated with Monte Carlo codes.
 Inelastic collisions: here, a more violent reaction between pro-
jectile and target occurs, where total kinetic energy is not
conserved. The projectile may knock out secondary particles
(protons, neutrons, deuterons, ’s, etc.) from the nucleus and
break into fragments if it is an ion.
The probability P(x) of not having undergone a given nuclear
interaction after traveling distance x in a material is given by:
P (x) =
N(x)
N(0)
= e
  xint ; (8)
where N(0) is the number of incident particles, N(x) the number
of incident particles after a distance x, int the mean free path or
interaction length. The latter is given by int = AtNA , where  is
the total cross section. Since there are some important differences
in modeling the nuclear interactions for proton and heavier ions,
we discuss them separately.
2.2.2. Nuclear Interactions of Protons
It is usually assumed that a proton hitting the atomic nucleus initi-
ates a series of nucleon-nucleon collisions, which leads to emission
of protons, neutrons, light fragments, and to equilibration of the
remnant nucleus. This process can be described as a sequence
of three stages (29, 30), displayed schematically in Figures 4 and
5 (top):
 (Generalized) Intra-nuclear cascade (INC)1: this model is com-
monly used to describe nuclear interactions of nucleons with
energies above 50MeV to hundreds of GeV. Originally pro-
posed in the fourties by Serber and Heisenberg (31), and suc-
cessfully implemented in the sixties by Bertini et al. (32), it
forms the basis for nuclear interactions in most modern MC
codes. The basic idea is that the incident particle interacts with
quasi-free nucleons in the target nucleus through a series of
two-body interactions. The target nucleus ismodeled as a Fermi
gas of cold, free, nucleons. The nucleons inside this intranuclear
medium are accounted for by a nuclear density distribution, a
nuclear potential, and the Pauli exclusion principle. This “free”
1The intranuclear cascade refers to the cascade inside the nucleus, as opposed to the
inter-nuclear transport of a particle from one nucleus to another.
nucleon approach is justified if the De Broglie wavelength h of
the incident particle is much smaller than the average distance
<d> between the nucleons in the material nucleus, and much
smaller than the mean free path N inside the nucleus:
h =
2~
p
 hdi =

3
4N
1=3
(9)
h =
2~
p
 N = 1
N
(10)
where  is the proton-nucleon cross section and N is the
intranuclear density (typically 0.17 nucleons/fm3 at the cen-
ter of nuclei). Another requirement for this approach to be
valid is that the time in which a collision happens is smaller
than the time between the collisions, so that they take place
independently. For radiotherapeutic energy ranges, it is not
immediately obvious that this approach is valid. For instance,
a proton of kinetic energy 250MeV has h ~ 1 fm, which is
roughly the same as<d>,making the condition in Eq. 9 invalid.
It turns out that the INC model works surprisingly well at
much lower energies than onewould expect, thanks to quantum
effects that increase the effective mean free path of nucleons
in the nuclear medium, like Pauli blocking, nucleon-nucleon
correlations, etc.
Once a nuclear interaction happens, the code has to model the
outcome. For therapeutic proton energies, only elastic scatterings
occur because these energies below the pion production threshold
of 290MeV. The final state particles in the scattering process are
called secondaries. The time in which they are produced corre-
sponds to the time-scale of strong interactions: 10 22 10 23 s.
The secondaries have high energy and can scatter again in the
same nucleus, or escape, etc. Not only protons and neutrons can be
emitted, but also light nuclear fragments of high energy, through
the coalescence mechanism, in which emitted nucleons, which
are near in phase space, are grouped. All particles are tracked
down until they are all below a given energy threshold, usually a
few tens of MeV. This process is called an intranuclear cascade.
The description of this process is highly complex, because all
secondaries must be transported through the nuclear medium
correctly, requiring accurate descriptions of the nuclear density,
quantum effects, the nuclear potential, binding energy, Fermi-
motion, and so on. A thorough description of the physics and
useful references can be found in Ref. (29, 30).
 Pre-equilibrium: in this stage, the energy of the particles in the
cascade has reached a lower limit, usually a few tens of MeV,
but the nucleus is not yet in thermal equilibrium. It is commonly
modeled inMC codes according to the excitonmodel (33, 34), a
semiclassical model introduced to explain high-energy emitted
particles in nuclear reactions. The evolution of the nuclear reac-
tion is also pictured as successive nucleon-nucleon collisions,
but within a particle-hole, or “exciton,” formalism, where nucle-
ons are excited from within the Fermi sea, leaving a hole. Pro-
tons, neutrons, and light fragments (through coalescence) are
emitted and the residual nucleus is left in an equilibrium state,
with a certain excitation energy shared among the remaining
nucleons.
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FIGURE 4 | Schematic display of stages in a nucleon-nucleus interaction relevant for radiotherapy, together with time scale and energy of interacting
particle.
FIGURE 5 | Top: sketch of a possible nucleon-nucleus reaction in proton therapy, whereby a neutron is created. Bottom: sketch of nucleus-nucleus reaction in
heavy ion therapy, with creation of light fragments.
 De-excitation step: depending on themass of the target nucleus
and on the energy left, the nucleus can dissipate its remaining
energy in several ways.
 Nuclear evaporation according to the Weisskopf-Ewing
approach (35). Here, light fragments (, d3,H3, He) with
kinetic energies of a few MeV can be successively emitted
from the excited nucleus, similar to evaporation from a hot
system.
 Fission: the excited nucleus breaks into two fragments:
applies to high Z nuclei only, roughly Z & 65. Apart from
implants, high-Z nuclei are not found in the human body and
this process is hardly relevant here.
 Fermi-breakup (36): this mechanism applies to light nuclei
(usually A . 16), where the excitation energy of the
excited nucleus may be larger than the binding energy
of some fragmentation channels. In this case, the excited
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nucleus disassembles in one step into smaller fragments.
Fermi-breakup is relevant for radiotherapy, because the
human body is mainly composed of low-Z nuclei.
 Gamma emission: What’s left after the previous stages is a
residual nucleus, with may be still somewhat excited. The
final excitation energy is given off through the emission of
 rays.
The first two steps are often referred to as “dynamic” stages of
the process, with an overall time scale of about 10 22 s, while the
last step is “slow,” typically 10 18 10 16 s. It must be noted that
the emission of secondary particles in proton therapy is entirely
due to the target nuclei, as was displayed in Figure 5 (top).
2.2.3. Nuclear Interactions of Heavy Ions
The fundamental difference between nucleus-nucleus reactions
and nucleon-nucleus reactions is that the incoming nucleons are
not free. This has some important phenomenological implica-
tions. Most models for nucleus-nucleus interactions are variants
of the “abrasion-ablation” model. During the fast stage (abra-
sion, time scale ~10 22 10 23 s), the projectile and target nuclei
overlap, resulting in a kind of reaction zone. An excited quasi-
projectile is formedwithmuch of the initial velocity, a quasi-target
fragment at rest, and several excited light fragments. During the
slow step (ablasian, time scale ~10 18 10 16 s), the remaining
projectile, target and light fragments de-excite by evaporating
light nuclei or fragments. It must be noted that in this case both
target and projectile-nuclei can fragment, as opposed to proton
irradiation, where only the target-like nuclei can fragment. This
is illustrated in Figure 5, showing a sketch of a nucleus-nucleus
interaction. The projectile fragments travel further in the forward
direction, loosing energy through ionization and undergoing fur-
ther interactions. These fragments have approximately the same
velocities and directions as their mothers, but larger ranges than
the primary ions because range scales with A/Z2. This leads
to the characteristic tail beyond the Bragg peak (see Figure 2,
right). The evaporation products from the projectile fragments
are evaporated isotropically in the reference frame of the projec-
tile fragment. The target fragments have short ranges and high
stopping power, and their evaporation products are evaporated
isotropically in the reference frame of the target fragments.
For describing the dynamic stage of the reaction, various mod-
els have been developed, differing mainly in the treatment of the
nuclear field affecting the propagation of the particles inside the
nucleus.
 Intra-nuclear cascademodel, for high-energy nuclei, with ener-
gies above about 100MeV/u. The description is similar to what
was outlined above for protons. The highly excited nuclei loose
energy through a series of two-body reactions and scatter-
ing off quasi-free nucleons. More than one nucleon-nucleus
interaction can take place in one nucleus-nucleus collision.
 Quantum molecular dynamics (QMD), for energies from 50
to about 400MeV/u. This model can be seen as sophisticated
form of the INC model. Here, each nucleon is described by
a gaussian wave packet, and all nucleons in the projectile
and target nuclei are participants in the collision process. By
minimizing the Hamiltonian that describes nucleon-nucleon-
interactions in the overlapping projectile and target nuclei, it
predicts the formation of heavy or light nuclei and secondary
protons and neutrons. Because of their complexity, these mod-
els are generallymuch slower inMC codes than the normal INC
model.
 Boltzmann-Master-Equation (BME): this is a sophisticated
model to simulate the pre-equilibrium stage, describing the
thermalization of composite nuclei for projectiles with ener-
gies below 100MeV/u down to the evaporation/fission/breakup
stage. Based on a set of time-dependent transport equations,
BME describes how a statistical state far from equilibrium
evolves to an equilibrium state, through a sequence of two-
body interactions and emission of unbound particles (neu-
trons/protons) and clusters (heavy/light nuclei).
For the de-excitation phase in nucleus-nucleus interactions,
the same models as those already described for nucleon-nucleus
interactions are used: evaporation, fission, Fermi-breakup, and
gamma emission.
2.2.4. Consequences of Nuclear Reactions
There are some important practical consequences of nuclear inter-
actions in hadron therapy:
 Nuclear reactions cause a significant loss of beam fluence. The
number of particles left at depth x depends on the inelastic
nuclear cross section through the relation in Eq. 8. For instance,
for 160MeV protons hitting a water target, roughly 20% of the
incident protons will be lost at the Bragg peak position at about
16 cm (8). For carbon ions, this number is much higher: for
290MeV/u carbon ions impinging on water, in average 50% of
the ions have undergone a nuclear reaction at the end of range
at around 16 cm (37).
 The dose distributions are modified. In the buildup region of
the Bragg curve, secondary particles contribute considerably to
the total energy deposition. Moreover, the height of the Bragg
peak is modified. In addition, in case of heavy ion irradiation,
dose is also delivered beyond the Bragg peak. Finally, the low
energetic secondary particles (including neutrons), which are
typically emitted at larger angles, contribute to the “low dose
envelope” around the beam. Even though the dose contribu-
tion of a single pencil beam is tiny, when combining thou-
sands of them, the dosimetrical and biological effects cannot
be neglected (38, 39), because the charged fragments can be
particularly damaging (see Section 2.3).
 Various types of secondary particles are produced, which can
be used for particle range verification. All three stages of the
nuclear reactions contribute to the production of secondaries.
The INC and pre-equilibrium stage mostly lead to production
of high-energy secondary particles (with energies that may
exceed even a hundred MeV), emitted mostly in the forward
direction in the laboratory frame. The slow part of the nuclear
interaction leads to lower energy secondaries, emitted more
or less isotropically in the center-of-mass frame of the mother
nucleus. In the case of ion projectile emissions, this implies
mostly forward in the laboratory system due to the kinematic
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boost. Three types of secondaries are used for rangemonitoring
in hadron therapy:
 + emitting isotopes: among the many fragments produced
during irradiation are + emitting fragments. Table 1 shows
the most frequently produced + emitters in a human body
treated with proton therapy together with their half-lives and
the incident proton threshold energy. Other reactions are
listed elsewhere (40). Depending on the value of their half-
life, the + emitters emit at a later time a positron, which
after traveling a small distance (of order mm), annihilates
with an electron in the medium into two coincidence gam-
mas of 511 keV. These can be measured with a PET detector,
enabling to extract information about the beam path. In
Section 4.2, we come back to the PET method.
 Prompt gammas, which accompany the nuclear reactions
along much of the proton path. Prompt photons are emitted
with energies ranging from 0 to about 10MeV. More details
and energy spectra will be discussed in Section 4.3.
 Charged fragments are produced, which can possibly be
measured and used for verifying particle range, will be dis-
cussed in Section 4.4. The secondary particles are usually
characterized by energy spectra and double differential cross
section measurements, i.e., particle fragment yields as a
function of their energy, at different angles.
2.3. Dosimetry Considerations
The absorbed dose D in a patient is related to the stopping power
by Gottschalk (8):
D(Gy) = 1:602 10 10  F dE
dx
1

(11)
where F is the particle fluence in cm 2,  the target density in
g/cm3, and dE/dx the stopping power in MeV/cm. For clinical
dose calculations in particle therapy, the mass stopping power
((dE/dx)/) is obtained from stoichiometric calibrations curves,
which link CT Houndsfield units in each voxel to mass stopping
power values, such as proposed by Schneider et al. (42).
To estimate biological effects, considering the physical dose
proves to be inadequate because biological damage caused by
radiation depends, e.g., strongly on the particle type and energy.
Although it is beyond the scope of this article to discuss biological
effects, a few concepts are relevant. The linear energy transfer
(LET) of a particle beam is the energy deposited locally per unit
path length, on microscopic level. Particles with high-LET such
as 12C ions cause more lethal damage to the cancerous cells than
proton or photon beams. Therefore, each ion type has a relative
biological effectiveness (RBE) assigned, defined as the ratio of
biological effectiveness of one type of ionizing radiation relative
to X-rays, given the same amount of absorbed energy. The RBE in
the Bragg peak region is close to 1 for protons (43) and between 3
and 4 for Carbon ions (44). For the latter, it must be included in
treatment planning (45).
2.4. Modeling Uncertainties and Validation
Two major uncertainties in calculating the stopping power and
particle range inMC codes are thematerial density and the ioniza-
tion energy Ie in water. Stopping powers deduced from CT scans
TABLE 1 |Most frequently occurring nuclear reaction channels for positron
emitter production in proton therapy.
+-emitter Half-life
(min)
Reaction
channel
Threshold energy
(MeV)
15O 2:037 16O(p,pn)15O 16:79
11C 20:385 12C(p,pn)11C 20:61
14N(p,2p2n)11C 3:22
16O(p,3p3n)11C 59:64
16O(p, d)11C 27:50
13N 9:965 16O(p,2p2n)13N 5:66
14N(p,pn)13N 11:44
30P 2:498 31P(p,pn)30P 19:7
38K 7:636 40Ca(p,2p2n)38K 21:2
Adapted from Ref. (40, 41).
suffer additionally from uncertainties like the calibration of the
CT scanner, conversion HU to stopping power. The dependence
on Ie is only logarithmic, but variations in the evaluated value
give range uncertainties of about 1–2% formono-energetic proton
beams (46), and even larger range uncertainties were found for in
patient tissues (47). In addition, the accuracy of stopping power
and range calculation depends also on other factors, like the
accuracy of the knowledge on the particle energy of the machine,
the precision and accuracy of the measurement device, the step
sizes in the MC code, the accuracy of the beamline description,
the treatment head, and so on.
Stopping power models in Monte Carlo codes used in medical
physics are usually benchmarked with standard quality assurance
(QA) in-house dosimetry measurements on homogeneous and
heterogeneous targets, typically performed with ionization cham-
bers, calorimeters, and Faraday cups. With the latter, it is pos-
sible to measure the longitudinal charge distribution of primary
and secondary particles, and to separate the nuclear interaction
component from the electromagnetic component. Lateral scatter-
ing models can be validated by measuring lateral dose profiles.
The validation of MC codes at therapeutic energies is important,
because manyMC codes have originally been developed for high-
energy physics, pertaining to different energy regions.
Uncertainties in modeling nuclear interactions come mostly
from uncertainties in cross sections, whereby total cross sections
and double differential (energy and angle) cross sections are most
relevant. The size and impact of these uncertainties is strongly
dependent on the purpose of themeasurement: dosimetry, shield-
ing, non-invasive range monitoring, and so on. Especially when
parameterizations used in MC codes are based on a few mea-
surements or when no data are available at all and models must
be relied on, uncertainties can be substantial, as is the case for
instance for production of + emitters. Additional uncertainties
apply when tissue composition is deduced from CT scans. We
come back to this in Section 4, where non-invasive range ver-
ification techniques are discussed. Uncertainties on total cross
section calculations are quantified by Sihver et al. (48), present-
ing comparisons of various nuclear interaction models with each
other and with experimental data in an energy range relevant for
radiotherapy.
Although dosimetry can certainly help to validate nuclear
interaction models, it is often impossible to perform direct
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experimental validation of the nuclear models in MC codes.
A first validation of nuclear interaction models, which can be
done in-house, is Faraday-cup measurements. Charged fragment
production is generally validated with experimental data collected
over the years of various thin and thick target measurements,
including both integral and differential quantities. An example
of a recent experiment contributing to the collection of relevant
data is the Fragmentation of Ions Relevant for Space and Ther-
apy (FIRST) experiment (49), aiming at cross section measure-
ments for projectile-target combinations and energies relevant
for ion beam therapy. Selected examples of the validation of MC
codes relevant for non-invasive range monitoring will be given in
Sections 3 and 4.
3. MC Codes
In this section, we summarize relevant features of the three most
frequently used MC codes in hadron therapy studies: Geant4,
FLUKA, andMCNP6/X. For each, we discuss transport and inter-
actions, as well as the validation for hadron therapy simulations:
depth-dose profiles, nucleon-nucleus interactions, and nucleus-
nucleus interactions.While we describe in this section the general
aspects like dose calculations and secondary particle production,
in Section 4 we will narrow the focus to range monitoring. Exten-
sive reviews about the general use of MC codes in radiotherapy
can be found elsewhere (10, 11).
3.1. FLUKA
FLUKA (50, 51) (FLUktuierende KAskade) is a general purpose
MC generator for the transport and interactions in matter of par-
ticles from a few keV to cosmic ray energies. Originally developed
for high-energy physics, it is nowadays widely used for shielding
applications, detector design, cosmic ray showers, and medical
physics. The code is written in FORTRAN.
3.1.1. Particle Transport and Interactions
Charged particle transport is done through a Multiple Coulomb
scattering algorithm (52) based on Moliere’s theory, with Fano
corrections, and supplemented by an optional single scattering
method. Ionization energy losses are based on statistical approach
reproducing ionization and fluctuations therein (53, 54), includ-
ing  ray emission and energy straggling.
Hadron-nucleus interactions are modeled in FLUKA with the
PEANUT (Pre-Equilibrium Approach to NUclear Thermaliza-
tion) model (30, 51), which is valid in a very broad energy
range, from reaction threshold up to a few tens of TeV. This
model simulates the first two stages of nuclear reactions described
in Section 2.2.2. The intranuclear cascade (INC) stage includes
many sophisticated features, including nuclear potential effects
like curvature of the path, and quantumeffects, like Pauli blocking,
nucleon-nucleon correlations, etc. The pre-equilibrium stage is
based on the exciton formalism from Blann (34). A coalescence
algorithm is used for emission of composite projectiles. PEANUT
ends when all particles are below a certain threshold, of the order
of 10–20MeV. The final relaxation step in FLUKA includes mod-
els for simulating nuclear evaporation, fission, Fermi-breakup
(A 17), and gamma emission. Recently, a direct deuteron forma-
tion mechanism has been added in FLUKA (55). Cross sections
are based on parameterized fits and tabulated data, when avail-
able. Otherwise, they are calculated with appropriate models. For
low energy neutron transport, FLUKA is linked with ENDF and
JENDL.
Nucleus-nucleus interactions are handled in FLUKA through
interfaces to event generators, which simulate the dynamic part
of the nucleus-nucleus interaction. Between 100MeV/u and
5GeV/u, a relativistic quantum molecular dynamics (rQMD)
model is used (56). Below 100MeV per nucleon, nucleus-nucleus
collisions are treated following theBME theory (57). Thesemodels
are all coupled to the internal FLUKAmodels for the slow phase of
the interaction through evaporation/fission/breakup and gamma
emission. For patient simulations, 3-D voxel geometries like CT
scans or other 3-D descriptions of human body can be read by
FLUKA. FLUKA Advanced InteRface (FLAIR) is a modern user-
friendly interface to FLUKA, which facilitates editing input files,
execution of the code, and visualization of the results.
3.1.2. Validation
Depth-dose profiles are important to check the validity of both the
electromagnetic and hadronic physics. FLUKA simulations have
been thoroughly validated with experimental depth-dose data for
protons and heavy ions (19, 51, 58). An example for protons is
given in Figure 2 (left), showing the comparison of measured
depth dose profile and the FLUKA simulation for various energies.
Hadronic interactions in FLUKA have been extensively bench-
marked against a variety of experimental data (51, 55, 59, 60).
An example relevant for proton irradiation is shown in Figure 6
(left), showing the simulated and measured secondary neutron
double differential energy spectra, resulting from 160MeV pro-
tons impinging on a Zr target. Still for proton irradiation, Figure 6
(right) shows the validation of the production of the + emitter
11C from proton irradiation of a 12C target. Also, longitudinal
charge distributions of proton beamsmeasured with Faraday cups
have been compared with FLUKA simulations to test the nuclear
models (54).
For 12C irradiation, Figure 7 nicely demonstrates the reliabil-
ity of the nucleus-nucleus interaction models. In this study by
Mairani et al. (60), simulations were compared with measure-
ments (63) of secondary particles behind a 15.9 cm water target,
irradiated with 400MeV/u 12C-ions. The transmitted primary
beam and the angular distribution of the secondary fragments
were measured. This plot demonstrates that the MCS model
together with the nuclear interaction models describes absolute
yield and angular distribution of the 12C beam and the produced
fragments.
The performance of FLUKA to simulate the specific reaction
products like + emitters and prompt ’s will be shown in
Section 4.
3.2. Geant4
Geant4 (64) is an open-source modern MC toolkit for simulating
the passage of particles in matter, written in C++. Originally
designed for the LHC experiments, its use has been extended
to medical physics, space science, nuclear physics, accelerator
physics, and so on. A set of standard physics settings for proton
therapy was proposed by Jarlskog and Paganetti (65), but this
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FIGURE 6 | Left: double differential energy spectra of emitted neutrons at
different angles, from 160MeV protons impinging on a Zr target.
Histograms are FLUKA results, points are experimental data from Ref. (61,
62). Reproduced from Ref. (51), with permission. Right: cross section for
nat12C(px)11C production from protons irradiation as computed with
fluka2013.0 (red, upper curve), and fluka2011.2 (blue, lower curve)
compared with data retrieved from the EXFOR library (28). Reproduced
from Ref. (55), with permission.
prescription has been modified. Below we discuss the most rel-
evant Geant4 physics models that are commonly used for hadron
therapy simulations. Details and references can be found in the
Geant4 manual (64) and in dedicated lectures (37).
3.2.1. Particle Transport and Interactions
Electromagnetic energy losses for hadron therapy studies are usu-
ally based on the so-called “electromagnetic standard package
option 3” list. Protons with energy above 2MeV are in Geant4,
simulated according to the Bethe-Bloch formula, while below
2MeV stopping power parameterizations are used. The multi-
ple scattering model is based on Lewis theory (22). For range
straggling, appropriate fluctuation models are provided.
Concerning hadronic interactions, Geant4 offers various mod-
els. Starting with protons, the dynamic part of inelastic nuclear
interactions can be simulated with the Binary Cascade Model
(BIC). This model simulates the INC stage described in Section
2.2.2 and includes relevant nuclear potential effects and quan-
tum effects, similar to FLUKA. This can be followed by a pre-
equilibrium stage (“precompound” model), which is based on the
exciton formalism fromGriffin (33). Geant4 also offers alternative
models to BIC: the intra-nuclear cascade Liège (INCL) model
from Boudard et al. (66), and the Bertini-model (32), differing
in many aspects, including the treatment of the nuclear potential,
nuclear density, and coalescence. For simulating the de-excitation
step, Geant4 includes several possibilities: standard evaporation
model based on the Weisskopf-Ewing approach (for emissions of
nucleons and light fragments, up to 4He), generalized evaporation
model (GEM, including also emissions of heavier fragments),
fission, multi-fragmentation (for nuclei with excitation energy
above 3MeV/u), Fermi-breakup (A< 17 and Z< 9), and gamma
emission. To evaluate nuclear cross sections, Geant4 is linked to
various nuclear databases, including ENDF, and when no data are
available calculations are used.
For heavier projectiles like 12C, Geant4 provides various possi-
bilities. The dynamic stage of the nucleus-nucleus interactions can
be simulated with the G4BinaryLightIonReaction (BLI) model,
a semi-classical INC model, but extended to take into account
that more than one nucleon participates in the reaction. Geant4
also offers the sophisticated G4QMDReaction model, a newly
implemented nucleus-nucleus interaction model based on QMD.
Alternatively, the INCL++ (Intra-Nuclear-Cascade Liège) model
can be used. All of them must be coupled to the aforementioned
de-excitation models.
3.2.2. Validation
Starting with protons, good agreements between measured and
simulated depth-dose profile were reported in Ref. (67, 68).
Geant4 was also shown to satisfactorily describe lateral beam
widening (68), although others reported disagreements (67).
Hadronic interactions were also validated against measured Fara-
day cup data (65). For carbon ion therapy, various groups reported
good agreements of dose-depth profiles, including the fragmenta-
tion tail (20, 69–71), an example of which is shown in Figure 2.
Several authors investigated the validity of nuclear fragmenta-
tion models for particle therapy. Much work has been reported
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FIGURE 7 |Measurements (63) (circles) and FLUKA simulations (histograms) of angular distributions of a carbon beam (left top) and secondary
fragments (others) measured behind a 15.9 cm water target, irradiated with a 400MeV/u 12C ions. Reproduced from Ref. (60), with permission.
by Pshenichnov et al. (69, 72, 73), making use of a dedicated
framework MC model for Heavy-Ion Therapy (MCHIT). Com-
parisons between simulated and measured depth-dose curves,
nuclear fragmentation build-up curves, angular distributions, and
yields of secondary particles (including + emitters) were per-
formed for protons and heavier ion beams impinging on homoge-
neous targets, leading to improvements in the nuclear modeling
in Geant4. MCHIT is also currently being used for validating
microdosimetric models (74).
More recently, validations of the newly implemented Geant4
models relevant for nucleus-nucleus interactions have been per-
formed. Böhlen et al. (59) reported a good agreement of the
QMD model with data in describing nuclear fragmentation in
carbon irradiations. Also, Robert et al. (75) studied depth-dose
profiles and secondary particle production in proton and carbon
therapy for Geant4 and FLUKA. Comparing depth-dose profiles
and energy spectra at various angles of charged particles and
prompt gammas, they identified the main differences between the
codes. Absolute yieldswere found to differ by roughly 20 and 100%
for + emitters and prompt photons. Also, De Napoli et al. (76)
andDudouet et al. (77) presented comparisons betweenmeasured
and simulated double differential energy spectra, including the
BIC, QMD, and INCL++ models, for mono-energetic carbon
beams impinging on various thin targets. None of the models
could satisfactorily describe yields, angular and double differential
energy distributions.
Geant4 validation studies for + and prompt gamma emissions
will be discussed in Section 4.
3.2.3. Geant4-Based Applications
Because the high level of experience required to use Geant4 has
proven to be a barrier for clinical usage, several user-friendly tools
making use of the Geant4 physics have been developed.
Geant4 Application for Emission Tomography (GATE) (78)
is an open-source MC framework making use of the Geant4
libraries. Originally dedicated to PET and SPECT systems, GATE
also offers the possibility for hadron therapy simulations, includ-
ing in vivo range monitoring using PET (79). GATE allows
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simulating very complex geometries like commercial PET or
SPECT scanners, time dependent quantities phenomena, and it
also offers image reconstruction tools.
Another example is Tool for Particle Simulation (TOPAS)
(80), a simulation tool dedicated to proton therapy simula-
tions. Recently, an extensive validation of TOPAS has been per-
formed for proton therapy treatments with the passive scattering
technique at MGH (81), based on routinely performed quality
assurance (QA)measurements (lateral and longitudinal dosemea-
surements, and so on). TOPAShas been used for range verification
studies with prompt gamma imaging, as will be described in
Section 4.3.2.
Particle therapy simulation framework (PTSIM) (82) is a
Geant4 software tool which can be used to model a complete
hadron therapy treatment, including beam delivery system, a
treatment head, and patient data obtained from CT images. It has
been used for carbon therapy simulations with the facilities in
Japan.
Finally, Geant4-based architecture formedicine-oriented simu-
lations (GAMOS) (83) is another Geant4-based simulation frame-
work aimed at nuclear medicine simulations, including hadron
therapy applications.
3.3. MCNPX/6
3.3.1. Particle Transport and Interactions
Monte Carlo N-Particle version 6 (MCNP6) (84) is a general pur-
pose MC generator for simulating radiation transport and inter-
actions in matter. MCNP6 is the result of merging and extending
the older MCNP5 (85) and Monte Carlo N-Particle eXtended
(MCNPX) (86) codes, written in FORTRAN.
Continuous ionization energy losses are modeled analytically
according to the Bethe-Bloch formula, using ionization potentials
recommended by the ICRUdata. Energy straggling is based on the
Vavilov straggling model (87), and multiple scattering is based on
Rossi’s theory (88).
At present, MCNP6 has 5 different models for simulating
nuclear interactions for medical physics (84): CEM03.03, Bertini,
INCL+ ABLA, LAQGSM03.03, and ISABEL. For proton ther-
apy simulations, the Cascade-Exciton Model (CEM) is currently
recommended and is the default option. This model, originally
proposed over 30 years ago in Dubna (89) and refined over the
years, incorporates all three stages of nuclear reactions described
in Section 2.2.2. The INC description includes many important
aspects such as quantum effects, nuclear binding energies, coales-
cence, and so on. The pre-equilibrium stage is modeled with the
exciton formalism, and evaporation/Fermi-breakup/fission can be
used for the final relaxation step. The second model, Bertini (32),
was successfully used in the past for proton therapy simulations
(90–92), but performsworse in describing angular distributions of
secondary particles, and is currently notmaintained anymore. The
third model, Intra nuclear-cascade Liége (INCL) model (66), can
alternatively be used in combination with the ABLA evaporation
model, but is slower.
To simulate nucleus-nucleus interactions in heavy ion therapy
simulations like 12C, the fourth model, Los Alamos version of
the Quark Gluon String Model (LAQGSM) (29) is suggested. As
the CEM model, LAQGSM describes all three stages of nuclear
interactions, and is valid over a large energy range even up to 1
TeV. However, the description of INC stage is entirely different
from that in the CEM model, taking into account the time of
interactions, the so-called “trawling effect,” etc. (see more details
and further references in (29)). LAQGSMmodels the interactions
of fast cascade particles (called “participants”) with nucleon spec-
tators of both the target and projectile nuclei and includes also
interactions between two participants. The modeling of the pre-
equilibrium stage and final relaxation stage is similar to the CEM
model. Finally, the fifth nuclear interaction model, ISABEL, was
used in the past for simulating nucleus-nucleus interactions, but
is no longer updated.
Below 150MeV, MCNP6 uses nuclear data libraries (26, 93)
evaluated frommeasured cross section data and calculations with
appropriate nuclear models. At higher incident energies, nuclear
reaction models mentioned above are used.
Concerning the usage of 3-D patient descriptions, MCNP6
includes the possibility to import 3-D voxel geometries like CT
scans.
3.3.2. Validation
Longitudinal and lateral dose distributions in MCNPX and
MCNP5 have been validated for proton therapy by various
research groups (90–92). The modeling of nuclear interac-
tions with MCNP6 with the CEM and the LAQGSM models
has been recently extensively validated by Mashnik et al. (94–
96). Fragmentation measurements from a vast set of recent
and older experiments were compared to MCNP6 simulations,
as documented in comprehensive Validation and Verification
(V&V) Los Alamos reports (94, 95). Comparisons included
total cross sections and double differential energy spectra for
neutrons, protons, and light fragments (up to 4He) produced
during irradiation of protons, light and heavy ions impinging
on many different homogeneous targets. Figure 8 demonstrates
an example of the validation, showing a measured double dif-
ferential neutron spectrum for a thin 12C target bombarded
with a 290MeV/u 12C beam, together with MCNP6 predic-
tions with the LAQGDM model. A very good agreement was
obtained.
Relevant for proton therapy simulations is a recent validation
of the CEM model in proton-induced fragmentation reactions
on low-Z targets (96), focusing on intermediate proton energies
(10MeV< 1GeV). For various fragment types produced dur-
ing nuclear reactions in different targets, measurements of total
inelastic cross sections, yields, excitation functions, and double
differential spectra of products were compared with simulations.
Overall, very satisfying agreements between data and MCNP6
were obtained.
3.4. Other MC Codes
Here, we will only briefly report on other MC codes that are used
for particle therapy.
Particle and Heavy Ion Transport code System (PHITS) (99)
is a general purpose MC particle and heavy ion transport code
written in FORTRAN, which can be used for simulating proton
and heavy ion treatments. Ionization processes are simulated with
the continuous slow down approximation. For low energy neutron
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FIGURE 8 | Experimental neutron spectra (97) at different angles from
a thin 12C target bombarded with a 290MeV/u 12C beam compared
with Japanese QMD calculations (98), the Bertini INC model (32)
coupled to an evaporation model (HIC), the Los Alamos version of the
Quark-Gluon String Model used as a stand alone code LAQGSM03.03
[see Ref. (29)], and with MCNP6 using the LAQGSM03.03
event-generator [see Ref. (94)]. Reproduced from Ref. (94).
induced reactions, PHITS employs the cross sections from the
JENDLnuclear data library. For nuclear reactions of higher energy
neutrons and other particles, various sophisticated models are
available, including the Microscopic Transport Model (JAM), the
JAERI Quantum Molecular Dynamics Model (JQMD), the INCL
model, and the INCL-ELFmodel. For details and references about
these models and their validation, see Ref. (99). PHITS can also
determine profiles of all secondary particles, including prompt ’s,
and perform microdosimetric calculations.
HIBRAC is a one-dimensional simulation tool developed by
Sihver and Mancusi (100) in FORTRAN, used in various clinics
worldwide in treatment planning for ion beam therapy. The code
is based on semi-empirical total and fragmentation reaction cross
section formulas for proton-nucleus and nucleus-nucleus reac-
tions, and models are used for calculating stopping power and
energy straggling. The code can accurately predict fluence, dose,
dose-average LET, track-average LET, and energy distributions
as a function of the penetration depth of light ion beams in any
solid or fluid target material. Predictions of the code have been
validated with experimental data (depth-dose profiles, fluence)
from the GSI and Chiba facilities. HIBRAC can also be used for
predicting PET profiles (101), albeit only in 1-D.
SHIELD-HIT (102) is another MC code dedicated to ion
therapy. It is a FORTRAN written code that is derived from
the SHIELD code, originally developed at the Joint Institute for
Nuclear Research in Dubna, Russia. It is possible to transport
nuclei, nucleons, anti-nucleons, pions, and kaons up to 1 TeV/u
and down to 1MeV/u. It includes all processes relevant for elec-
tromagnetic interactions (straggling, MCS, ionization losses) and
nuclear interactions. Nuclear fragmentation is handled by the
many stage dynamical model (MSDM), simulating all three stages
in nuclear reactions. The SHIELD-HIT code is primarily used in
particle therapy for calculation of stopping power ratios, fluence
correction factors, and anti-proton calculations.
Another MC code developed for treatment planning is the
VoxelMonteCarlo for proton therapy (VMCpro) code (103), a fast
MC framework, also written in FORTRAN. VMCpro simulates
proton transport in human tissue based on a condensed history
technique. The code is based on various approaches and parame-
terizations, for instance a simplified multiple coulomb scattering
algorithm and density scaling functions instead of actual material
compositions. Nuclear interactions are treated as corrections to
electromagnetic processes. Valid results for depth-dose predic-
tions were obtained with VMCpro, and being order of magnitude
faster than for instance FLUKA and Geant, the code is a valuable
tool for treatment planning.
PENELOPE is a MC code written in FORTRAN that was
originally limited to the transport and interactions of photons,
electrons, and positrons. It has recently been extended to pro-
tons (104) (PENH). The main motivation for the extension is to
provide the medical physics community with a fast and reliable
MC code for instance to perform dose calculations from treat-
ment plans. Dose distributions obtained with PENH have been
benchmarkedwithGeant4 (GATE) andFLUKApredictions (104).
4. MC Signal Modeling for In vivo Range
Verification
4.1. Introduction
In this section, we discuss the three most widely researched
modalities for in vivo non-invasive hadron therapy verification,
which exploit secondary particles produced in nuclear reactions:
PET (Section 4.2), prompt gamma (Section 4.3), and charged
particle imaging (Section 4.4). For each of them, we introduce the
technique and briefly discuss different detector types. The latter is
relevant here, because it can affect the way theMC predictions are
made. Furthermore, we describe examples of the MC predictions
and validation procedures adopted by various research groups,
and touch briefly on clinical challenges related to MC simula-
tions. Because the focus of our review is on the physics and MC
modeling, we do not discuss logistical, technical, and economical
issues related to clinical integration, image reconstruction, signal
analysis, clinical interpretation of detected range deviations, nor
do we discuss the expected sensitivity of the techniques. These are
discussed in other works (4, 10, 11). A brief comparison of the
three techniques will be presented in Section 5.
Finally, other imaging methods that are currently investigated
for treatment verification include proton radiography (105), pro-
ton tomography (106), and ionoacoustic imaging (107); however,
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we do not consider them here. The same applies for positron
emitting probing beams, such as for instance investigated at the
Chiba facility (108).
4.2. PET-Based Treatment Verification
4.2.1. Treatment Monitoring Strategies
In Section 2, we have seen how nuclear reactions of incident
protons and nuclei give rise to the production of + emitting
fragments. By detecting the two 511 keV photons by positron
annihilation, spatial distributions of the + decay points can
be obtained. Often one-dimensional profiles along the beam-
axis are chosen to display the activity along the beam path. In
Figure 9, such profiles are displayed for various incident beam
types impinging on a PMMA target. Normalization is arbitrary
here. Two things can be noticed. First, the shape of the + activ-
ity profiles of light beams is remarkably different from those of
heavier nuclei. While for the p, 3He, 7Li ion beams, the induced
activity is only due to positron-emitting target residuals produced
all along the beam path; for the 12C and 16O beams, there is an
additional contribution in the activity from + emitting projectile
residuals when they stop, near the end of range, explaining the
activity peak. Second, we see that no direct correlation exists
between +-activity and the dose, which is not surprising, being
based on different physics processes. Nevertheless, by comparing
the measured PET data with reference distributions, it is possible
to estimate whether the dose was delivered successfully. Large
discrepancies between expected and measured PET data indicate
problems in dose delivery. Such reference distributions are gener-
ally made withMC simulations on the basis of the treatment plan,
time-course of irradiation, the patient CT, detector geometry,
and imaging procedure (109). The application of PET to hadron
therapy dose monitoring has been studied for about 20 years and
is currently a well-established, although not widely used, method.
Recent reviews can be found for instance in Ref. (4, 41).
PET data acquisition strategies are usually categorized as
follows:
 In-beam data acquisition, where the PET system is integrated
in the beam delivery system and data are acquired during or
immediately after irradiation inside the treatment room (109–
117). Data-taking during irradiation is attractive, because this
allows detecting activity from 15O and other short-lived iso-
topes, and avoids having to deal with biological signal washout
in the human body. Moreover, no repositioning of the patient
is necessary. On the other hand, disadvantages include the
high costs for integration into the treatment site, geometrical
limitations on the detector, and the associated image artifacts. A
special challenge is acquisition during beam extraction, where
background from random coincidences tends to paralyze the
PET detectors (118). The most commonly chosen solution
in synchrotron facilities is to take data during spill-pauses,
although at cyclotrons data-taking during beam extraction was
shown to be feasible (115, 119).
 In-room data acquisition, where data are acquired quickly after
irradiation with a full-ring PET detector installed in the treat-
ment room. This methodology was explored at MGH (120,
121). The advantage is that signal washout is reduced, and
problems related to patient transport and repositioning are
minimized. Disadvantages include a longer treatment room
occupation time and difficulties in co-registration of the PET
image with the planning CT.
 Offline data acquisition, where data are acquired with a full-
ring PET after patient irradiation outside the treatment room
(122–125). The advantages are the low costs and the complete
angular coverage. However, the delay between particle deliv-
ery and monitoring greatly limits the offline method. Signal
decay and biological washout processes rapidly cause signal
degradation, which is difficult to model accurately (124, 126).
4.2.2. PET Systems for Treatment Verification
Depending on the data acquisition strategy, different detectors can
be used for PET-based treatment monitoring.
 Planar PET systems, for in-beammonitoring. A planar configu-
ration was used at GSI for in-beam PET monitoring of patients
treated with 12C ions (109, 111), using data acquired during
spill-pauses and after treatment. Planar configurations have
also been developed in Japan at Chiba (128) and have been used
to monitor patient treatments with 12C at the Kaswhiwa facility
(113). Moreover, a compact planar PET system enabling data
acquisition during and after treatment has been developed at
INFN and was tested on phantoms at CATANA (115, 119) and
CNAO (116). Adding TOF information could help in reducing
background to signal noise (129).
 Full-ring commercial PET scanners, which can be used only for
monitoring after treatment. Such scanners have been used for
in-room (120, 121) and offline data acquisition (122–125).
 Alternative geometries: ring-shaped PET systems are being
investigated in Japan for in-beam data acquisition, including a
dual-ring (130) and a full-ring (114) PET system, cut at a slant
angle. The latter geometry is promising, because it would repre-
sent the first in-beam systemwith complete angular acceptance.
Also, C-shaped and partial ring PET systems were studied with
GATE for in-beam PET (131).
4.2.3. Prediction of + Activity
Many different approaches have been used in research and clinical
studies for predicting the PET activity signal.Wedescribe them for
proton, carbon, and heavier ion therapy.
Starting with protons, pioneering studies performed by Parodi
et al. (122, 132) for offline PET monitoring of proton treatments
at MGH were based on FLUKA simulations. Rather than rely-
ing on the internal FLUKA nuclear cross sections, the activity
was calculated by folding the proton track length with external
experimental cross section data (132). For activity predictions in
patients, correction factors for biological washout were applied a
posteriori on the basis of the CT scan, where regions with low,
intermediate, and high perfusionwere identified. The reliability of
theMCpredictions turned out to depend on treatment site,mostly
because of problems in modeling biological washout (124).
More recent studies focusing on in-room proton therapy at
MGH used Geant4 for predicting PET activity distributions (120,
121, 133). First, they compared PET measurements on homoge-
neous targets with MC activity predictions using different cross
section data libraries. The cross section values that best described
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FIGURE 9 |Measured positron emission activity together with the dose distribution for irradiation of a PMMA target with different projectiles:
protons, 3He, 7Li, 12C, and 16O. Reproduced from Ref. (127), with permission.
the measurements were chosen for the patient MC simulations
(133). Including this tuning, the Geant4 predictions were success-
fully used for patient monitoring (120, 121).
A similar procedure was studied by Bauer et al. (134) for
offline PET data acquisition in proton therapy at HIT. FLUKA
was used to investigate the effect of directly including in-house
activity measurements for homogeneous materials into the simu-
lation. Fine-tuned cross sections turned out to reduce uncertain-
ties, improving the modeling of proton-induced positron-emitter
production.
Kraan et al. used FLUKA to predict the PET activity measured
in homogeneous targets during and after proton irradiation with
an in-beam PET system at the CATANA cyclotron (119) and at
the CNAO treatment facility (116). Figure 10 shows an example
of measurements performed at CNAO for irradiation of a PMMA
phantom with a homogeneous proton beam (top figures) and a
SOBP (bottom figures), together with the FLUKA simulation, for
various acquisition time intervals. A good agreement betweendata
and MC simulations was found.
In carbon irradiation, the signal modeling is somewhat differ-
ent, and other approaches have been applied. For the early PET
studies on patients treatedwith carbon ions at theGSI facility (109,
111), a dedicated MC simulation tool (POSGEN) was developed
by Pönisch et al. (135) for calculating the activity. A simplified and
fast simulation approach was applied, based on the assumption
that the dominant contribution to the + activity profile comes
from projectile residuals. The calculation was split in two steps:
a one-time step to calculate the activity from target residuals
assuming a homogeneous medium, and a patient and fraction
specific step to calculate the projectile contribution. The code used
relied on cross section models developed by Sihver et al. (100) to
handle nuclear interaction processes. It was validated and applied
clinically for the in-beam monitoring project at GSI (110, 111,
136), and also used for modeling the PET activity for moving
targets (137).
Following the improvements of the internal nuclear models
in FLUKA, Sommerer et al. (138) assessed the performance of
FLUKA by comparing measured and simulated activity profiles
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FIGURE 10 | Top: 1-D profile along the z-axis of the measured (black)
and MC simulated activity (red) induced by a 95MeV proton beam
impinging on a PMMA target during 118 s. Bottom: the same but for
the 2Gy treatment plan, delivered in 145 s. Inter-spill (left), beam-off
(center), and all together (right) are displayed separately. Adapted from
Ref. (116).
in homogeneous target irradiated with carbon and oxygen beams.
The code was extensively benchmarked with data and has been
used for offline-treatment verification after carbon ion therapy
of patients at HIT (125, 139). Figure 11 shows an example of a
measured and MC predicted activity profile along the beam-axis
for a glioblastoma patient treated at HIT.
Still regarding carbon treatments, Pshenichnov (70, 72, 73) has
assessed the performance of the Geant4MC code to describe PET
activity measurements at GSI, using the dedicated MCHIT tool
described in Section 3.2.2. However, these studies dealt mainly
with homogeneous targets, and were not extended to patients.
Various groups have compared + activity predictions from
different MC codes (101, 140, 141) with each other and with mea-
surements, including FLUKA, Geant4/GATE, MCNPX, SHIELD-
HIT, PHITS, HIBRAC, and POSGEN. These studies report large
differences up to 50% in yield between the codes and themeasure-
ments, but mostly because simulations were based on different
cross section models, confirming the need to use experimental
cross sections in MC codes, when possible.
For other ions thanprotons and carbon, only fewMCstudies for
PET-based treatment monitoring were performed. Pshenichnov
et al. (73) used Geant4/MCHIT to calculate the activity induced
in 3He treatments, and compared these predictions with data from
Fiedler et al. (142), but significant discrepancies were found. PET
measurements for mono-energetic 16O beams were presented by
Sommerer et al. (138), and compared with FLUKA simulations,
finding a good agreement. Finally, PET measurements with 3Li
were performed (143) but no MC calculations were included.
Besides predictions based on full MC, various attempts to pre-
dict the PET activity analytically were done, allowing for much
faster predictions. Parodi and Bortfeld (144) developed an ana-
lytical method to calculate activity by a convolution product of
dose and a number of filter functions. This approachwas extended
by Attanasi et al. (145), but never clinically applied. Solving the
inverse problem, i.e., finding the dose from activity measure-
ments, was also studied (146, 147) with deconvolution methods,
but the complexity of the problem makes it challenging to apply
to real patients. Recently, Miyatake and Nishio (148) developed a
promising analytical activity pencil beam algorithm.
Finally, there are treatment centers which do not use MC
simulations for treatment verification. At the Kashiwa facility,
treatment verification has been based on comparing the PET
distributions measured during the various fractions with first day
measurements (113). At the Hyogo facility, PET activity is directly
compared visually with the prescribed dose to verify the beam
path (149). A similar procedure but with markers was applied at
the Florida Proton Therapy Institute (123).
To summarize, different approaches exist for obtaining the PET
reference activity distributions. It is generally agreed on that MC
predictions provide the best reference distributions. So far, the
FLUKA and Geant4 generators have been used for providing ref-
erence distributions in clinical studies, yielding good agreements
for PET measurements in carbon and proton irradiation.
4.2.4. Challenges in Clinical Implementation
Many of the above studies have shown how PET treatment veri-
fication provides relevant clinical information. At the same time,
these studies have highlighted some important limitations in the
MC simulations, which should be resolved if PET is to become
a widespread treatment verification technique in hadron therapy.
Several issues remain to be addressed:
 Insufficient knowledge on cross section values, leading to
uncertainties in + yield and in absolute particle range, as
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FIGURE 11 | Top left: colourwash overlays of the planning CT image
(TP-CT) in the coronal view with the RBE-weighted dose distributions as
obtained from the TP system (TP dose). Top center: the simulated
activity pattern overlaid on the PET-CT image (Sim). Top right: the
measured PET image (PET) overlaid on the PET-CT image. The solid
green line marks the planning target volume. Bottom: the profile plot of
the simulated and the measured activity (solid) as well as the
corresponding CT image values (dashed) along the yellow line in panels
Sim and PET in beam direction. Reproduced from Bauer et al. (125), with
permission.
was shown by various studies. España et al. (133) reported
that cross section uncertainties on activity fall-off position
lead to a 1 and 5mm uncertainty on the activity fall-off posi-
tion, for 5 and 30min in-room data-taking, respectively. To
illustrate the problem, let’s consider Figure 6 (right), which
showed the production cross section of the + emitter 11C.
Although this plot shows large errors and conflicting data, it
is an example of an accurately known cross section. In fact,
for other + emitters (12N, 14O, 8B, etc), the situation is much
worse, having to rely on only very few, sometimes very old,
measurements including large errors to benchmark the codes.
Obviously, new cross section measurements for production
of various + emitters would be helpful. In particular, these
should include systematic, high quality, double differential
energy spectra, with different types of projectiles, energies, and
targets.
 Inaccuracies in MC predictions from the unknown elemen-
tal composition. While for dose calculations, the CT based
stoichiometric calibration is typically sufficient, this is not the
case for predicting quantities heavily relying on specific nuclear
reaction channels (150). The impact of CT calibrations is espe-
cially significant for proton therapy, where the + activity
comes entirely from target residuals. The uncertainty on distal
fall-off position of the PET signal was estimated to be about
1mm for proton therapy (150). For carbon ions, the depen-
dence is less pronounced (135). Additional information about
the tissue may be extracted from the characteristic time decay
curve of the PET signal (151) or fromMRI.
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 Inaccuracies in modeling biological washout, most relevant for
off-line imaging. Our goal was to describe the physics aspects,
and hence it is beyond the scope of this work to describe
biological aspects. However, it has been repeatedly reported in
offline PET studies that simulating biological washout correctly
is highly complex and is a major limitation of the offline PET
method.
 Speed and complexity of the MC simulations. The current
frameworks like FLUKA and Geant4 are too slow, require a
too steep learning curve, and too specialized knowledge to be
applied widely in clinical practice.
 Extension of PET as monitoring tool for treatments of moving
target, as for instance studied at Oncoray (137). The patient
studies discussed above mostly concern static tumors. PET
could be a valuable tool to monitor the accuracy of treatments
of moving targets, but modeling the expected signal withMC is
still largely uncovered.
 Automatic assessment of the predicted and measured activity
maps, as investigated by various groups (see for instance Ref.
(152, 153)).
 Translation of PET activity maps to dose. Despite the compli-
cated andmathematically ill-defined problem, new research on
this subject would be very valuable, because dose is an easily
interpretable quantity for physicians. The current PET treat-
ment monitoring is based on interpretation of activity maps,
which require special knowledge about the activity signal, and
is therefore much less appreciated by clinical personnel.
4.3. Treatment Verification with Prompt Gammas
As discussed in Sections 2.2.2–2.2.4, prompt gammas are emitted
as a result of nuclear reactions during particle delivery along
much of the particle path, with energies varying from 0 to about
10MeV (for typical spectra see Figure 12, to be discussed below).
We first briefly discuss the detectors, then describe MC vali-
dation studies with prompt gammas, and finally some clinical
challenges.
4.3.1. Prompt Gamma Detection Devices
The energies of prompt gammas from nuclear reactions are too
high for standard single gamma detection devices like SPECT to
be efficient, and dedicated detector designs are needed. There are
different prompt gamma imaging systems under investigation, of
which some are design studies based on MC simulations, and
others real prototypes. Let’s briefly discuss some of them.
 Collimated gamma cameras. By placing the camera at 90°
with respect to the beam-axis and moving the device parallel
to the beam-axis, a 1-D prompt gamma profile can be mea-
sured. This was the design used in the first studies where the
correlation between the Bragg peak position and the prompt
gamma emission profile was demonstrated, for proton (156)
and carbon (157) irradiation. This design has since then been
recycled by various research groups for proton therapy (158–
163) and carbon treatment verification (164, 165). To increase
the detection efficiency and to be able to measure the 1-D
profile without having to move the detector, an array-type
multi-slit camera has been designed usingMCNPX simulations
(166). Knife-edge-shaped slit cameras have also been inves-
tigated (154, 167, 168). Here, instead of a parallel collimator
a slit-collimator is employed. Promising measurements with
a collimator slit-camera prototype tested with clinical proton
beams have recently been presented by Perali et al. (168),
estimating a precision () on single spot range determination
of 2mm. Recently, Pinto et al. published a review of absolute
prompt gamma yields measured with proton- and carbon-ion
beamswith single-slit experiments (169). At phantom entrance,
the average number of detected prompt gammas was found to
be of order 10 4 per incident carbon ion and 10 5 per incident
proton.
 Compton cameras. Here, a multi-stage detector can measure
the initial energy and direction of the photons undergoing
Compton scattering in the detector. Various Compton camera
prototypes have been realized (170–174) and various detector
design studies have been performed with Geant4 MC simula-
tions (175–179). The advantage of the Compton camera is that
it has the potential to provide 3-D images.
 Other devices. Prompt-gamma timing camera (180). This is
a promising new method, where instead of the spatial posi-
tion the characteristic time-of-flight of the photons is used to
extract information about the particle range. The underlying
idea is that the transit time from phantom entrance to detec-
tor increases with the particle range, which causes measur-
able effects in timing spectra. Furthermore, energy-and-time
resolved prompt gamma detection has also been proposed (160,
163), and will be discussed below.
4.3.2. Prompt Gamma Monte Carlo Validation Studies
A large amount of simulation and validation studies have been
performed for prompt gamma imaging in proton and carbon
therapy. Below we discuss some selected examples, first for proton
and then for carbon therapy.
Starting with protons, Polf et al. (159) compared Geant4 simu-
lations (version 9.1) to estimate the prompt gamma ray emission
produced inwater, Lucite, and bone-equivalent plastic during pro-
ton irradiation.Using a collimated gamma camera, they compared
the acquired prompt gamma energy spectra with simulations,
finding an overall satisfying agreement.
The MCNPX code was tested by Smeets et al. (154), who
compared energy spectra measured with a knife-edge-shaped
slit camera with MCNPX predictions (154). When applying a
data-driven neutron background subtraction method, a satisfying
agreement was obtained between data and MC simulations for
the prompt gamma energy spectrum and yield. Without back-
ground subtraction, when the prompt gamma spectrum was con-
taminated heavily by neutron contributions, the description was
unsatisfying.
Verburg et al. (181) performed an extensive validation of the
nuclear cross sections of specific gamma-emission channels, iden-
tified by lines in the measured energy spectra, of the Geant4
(9.5) and MCNP6 codes, as well as for two pre-equilibrium reac-
tion codes (TALYS and EMPIRE), for protons up to 200MeV.
Cross section predictions as a function of incident proton energy
of the MC codes were compared to evaluated data from the
ENDF/B-VII database. Using the BIC model for Geant4 and
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FIGURE 12 |Measured and simulated (TOPAS) energy spectra at the end
of range of a monoenergetic 160MeV proton pencil beam impinging
along the central axis of a cylindrical PMMA target. Experimental setup
(A) together with measured and simulated energy spectra for different collimator
configurations (B–F). “Opening difference” is Collimator Open minus Collimator
Closed, and “Wall-difference” means No Collimator minus Collimator closed, i.e.,
a configuration in which neutron background is subtracted. Measurements from
Smeets et al. (154). Figure reproduced from Ref. (154, 155), with permission.
the Bertini model in MCNP6, significant differences were found
between measurements and predictions of the most important
reaction channels, mostly in the low energy region (<20MeV)
where the codes tend to underestimate the cross sections by
a factor two. The TALYS and EMPIRE values were somewhat
better.
Still focusing on protons, a recent study by Dedes et al. (182)
investigated the accuracy of Geant4 code (version 9.4) using the
BIC model for nucleon-nucleus interactions. Different measure-
ments of prompt gamma energy spectra with a collimated camera
placed at different angles (mostly 90° w.r.t. the beam axis) were
performed, and compared to Geant4 predictions. Additionally,
the measurements from Smeets et al. (154) were used for com-
parison. The prompt gamma yield was generally overestimated
using the Geant4 BIC model, evidencing the need for further
improvements in the nuclear models.
A similar study was recently performed with TOPAS (155),
where the same measured energy spectra from Smeets et al. (154)
were compared with TOPAS simulations, also using the Geant4
BIC model. In contrast to Dedes et al. (182), an overall good
agreement in yield and prompt gamma spectra between TOPAS
predictions and measurements were obtained, when subtracting
the neutron background. The results are shown in Figure 12.
Moreover, the accuracy of prompt gamma imaging was estimated
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for a clinical scenario. A 4mm accuracy was estimated for a
prostate tumor treatmentwith a dose of only 15 cGy deliveredwith
passively scattered protons, a promising result.
Closely related to range monitoring, research has been per-
formed to evaluate the sensitivity of the prompt gamma energy
spectra in proton therapy to tissue composition (160, 163, 183).
At the end of range, when the projectile energy has decreased
and only a few relaxation channels are possible, discrete lines in
the gamma spectrum are visible (see Figure 12). These have been
shown to be sensitive to the elemental composition of the sample
(160, 183). In particular, themeasured spectra can be used directly
as input in the MC predictions to increase their accuracy (163).
For carbon beams, the Geant4 performance for prompt gamma
predictions was tested in several studies using the older nuclear
INCmodels (184) and newly implemented QMDmodel (182). At
low energies (95MeV/u), the QMD model describes well energy
spectra and yields when tuning the free parameters in the model.
At higher energies, the observed remaining overestimation by
Geant4 comes from the secondary proton and neutron contribu-
tions, which are not correctly described by the BIC model, as was
seen also in the previously mentioned study by Dedes et al. (182).
Recently, the performance of FLUKA was investigated for
prompt gamma production in 12C irradiation of a PMMA target
(55). An example of a predicted spatial prompt gamma profile
along the beam path measured at 90°(from Ref. (184)) is given in
Figure 13, showing a good agreement.
Finally, there are studies exploiting a completely different type
of prompt gammas, coming from Cherenkov radiation from sec-
ondary electrons produced during particle irradiation (185). In
this context, a study by Yamaguchi et al. (186) measured low
energy prompt photons (around 65 keV) to verify the 12C range,
which could provide a complementary approach to othermethods
for range verification for shallow target treatments.
To summarize, for proton beams, a reasonable description of
the prompt gamma yield could be obtained, although disagree-
ments were reported as well, especially to describe neutron con-
tributions. Concerning carbon beams, QMDmodels are generally
still in a development status, but current implementations are
promising.
4.3.3. Challenges for Clinical Implementation
The clinical implementation of the prompt gamma technique
is still facing several challenges, which are discussed elsewhere
(4). Concerning MC modeling, we have seen that the accuracy
of the MC simulations has been much improved recently, but
many issues still remain to be improved. Eventually, the prompt
gamma imaging method will depend on comparisons between
data and expectations calculated from 3-D patient descriptions
like CT’s, just like the PET imaging method. Whichever mea-
surements will be performed (1-D, 2-D, 3-D spatial distribution,
timing profiles, energy spectra), the MC codes will provide the
reference. Current challenges in signal modeling to be addressed
include:
 Nuclear models in most MC generators are not fully satisfying.
Predicted cross sections are not always in agreement with data,
and the neutron background is poorly understood. New cross
section measurements at various angles for protons and carbon
beams on thin targets covering the whole range of therapeutic
energies would be useful (160, 163).
 Increasing the speed of the calculations is also important.
Research on how to perform faster and more efficient cal-
culations of prompt gamma yields was presented in recent
articles (104, 187). Separating the MC physics generation step
and the detector simulation step as done in Ref. (166) can
additionally help.
FIGURE 13 | Left: prompt photon yield at 90° as a function of depth for
a 95MeV/n 12C beam impinging on a PMMA target. The Bragg peak
position is at about 20mm. Data (red stars) are from Ref. (184),
re-evaluated as described in Ref. (169), and FLUKA simulations (blue
circles) are shown. Reproduced from Ref. (55), with permission.
Right: the same data, compared with simulations of Geant4 using the
QMD model with different values of a free parameter. Reproduced from
Ref. (182), with permission.
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 In-house validation of the applied MC codes. Each research
center has to validate its own MC framework using their own
beamline and detection system, as was shown to work best also
for PET monitoring. MC validation tests with the help of the
standard QA measurements as proposed in Ref. (155) should
be a starting point for validating the code.
 Performing data-MC comparisons for heterogeneous targets,
including patients. Although studies on heterogeneous phan-
toms have been initiated (188), much more research is needed
to verify the reliability of the MC codes when the phantom is
heterogeneous and when the elemental composition must be
obtained from a CT scan.
 Performing uncertainty analysis, for instance quantifying the
influence of CT calibrations, ionization potential, or nuclear
cross sections on the MC predictions, as has been studied for
PET imaging too.
4.4. Charged Particle Imaging
Another method which offers the possibility to determine the
particle range is the analysis of the charged particles that are
created during nuclear fragmentation in the patient (Section 2.2),
and which exit the patient (189, 190). This method has so far been
limited to carbon irradiation, where the amount of high-energy
secondary charged particles is larger than in proton therapy.
In the interaction vertex imaging (IVI) method, the trajectories
of the charged particles exiting from a target are reconstructed
and extrapolated back to their production point. Henriquet et al.
(191) presented a feasibility study for this technique in carbon
therapy, using Geant4 (9.2) simulations. An angle of 30° with
respect to the beam-axis was chosen to detect charged particles.
For homogeneous phantoms, milimetric precision was expected
when monitoring with single pencil beams of 2 105 carbon
ions. The approach was experimentally tested by Gwosch et al.
(192), measuring charged particles exciting from homogeneous
targets irradiated with carbon ions at HIT. The tracking device
was placed at an angle of 30° from the beam-axis. The accuracy for
monitoring the beam-range was found to be 1–3mm, but based
on pencil beams with much higher statistics than what is used
clinically.
Detection of secondary charged particles for range monitoring
was also investigated by others. Agodi et al. (193) and Piersanti
et al. (194) irradiated a PMMA target withmono-energetic carbon
ions with various energies. Trajectories of charged particles with
kinetic energies up to several tens of MeV were measured with a
tracking device, placed at 60° and 90° angle with respect to the
beam axis. A clear correlation between the measured 1-D profile
of the charged particle yield and the dose was found, and a reason-
able agreement with FLUKA predictions (see Figure 14). These
measurements at large angle are very valuable for the validation of
nuclear models in MC codes.
A large-area proton range telescope is being developed by
the TERA collaboration (195), with expected acceptance of
30 cm 30 cm perpendicular to the beam.
Current challenges in signalmodeling being faced for this range
monitoring technique are very similar to those alreadymentioned
in PET and prompt gammamonitoring. However, a very accurate
MC prediction of the angular distributions of the fragments is
even more crucial in this case, relying on prediction at large
angles. Double differential energy spectra are especially useful for
the validation of MC codes, such as recent measurements by De
Napoli et al. (76) andDudouet et al. (77). Concerning the detector,
the acceptance and efficiency should still be increased.
5. Discussion and Future Outlook
The enormous amount of literature written about range monitor-
ing demonstrates the worldwide interest in the subject. With the
number of particle facilities growing, and in view of the increas-
ingly considered hypofractionation schemes for dose delivery,
non-invasive particle range verificationmethodswill become even
FIGURE 14 | Left: FLUKA simulation of the depth-dose profile
(hatched histogram) superimposed on the longitudinal profile of
charged secondary particles (solid line) as a function of xPMMA, the
primary beam direction. Right: the corresponding data (histogram)
and data analysis (smooth line). Reproduced from Ref. (194), with
permission.
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more needed in the future. MC simulations are of prime impor-
tance in the development and application of range monitoring.
In this review, we intended to describe the physics modeling
and MC codes that are applied in the currently most widely
researched range monitoring techniques, and to highlight therein
the difficulties and challenges.
We have seen that the main inaccuracies in physics model-
ing have turned out to be very similar for the three techniques,
because they rely all on an accurate description of electromagnetic
and nuclear interactions of hadrons in matter. Summarizing, the
common inaccuracies include:
 Uncertainties in describing nuclear interactions, including
cross sections and interaction models. For PET, we saw in
Section 4.2.4 that cross section uncertainties can lead to uncer-
tainties in activity distal fall-off position of several millimeters.
New double differential thin and thick target cross sectionmea-
surements for specific reaction products in the entire energy
range of therapeutic protons and heavy ions are the best way
to improve the accuracy.
 Uncertainties in densities and elemental composition of the
target. For PET, such uncertainties were of the order of a mil-
limeter for proton therapy, as mentioned in Section 4.2.4. MRI
could possibly improve the knowledge on elemental composi-
tion, as well as evaluating the elemental composition during
range monitoring. For PET-based methods, the latter can be
done by measuring time-decay curves of the PET signal, as
was remarked in Section 4.2.4, while for prompt  monitor-
ing the discrete spectral lines could be used, as referenced in
Section 4.3.2.
 Uncertainties on the position of the Bragg peak, coming from
uncertainties in the ionization potential I and in the ionization
model. As was discussed in Section 2.4, variations in the mea-
sured value of I inwater lead to an uncertainty of several percent
in Bragg peak position. In-house Bragg peak measurements
could help to validate the MC code, thereby reducing this
uncertainty.
For PET treatment verification, these uncertainties can add
up to several millimeters, with nuclear interaction modeling as
main source of uncertainty. For prompt gammas and charged
particle imaging, the uncertainties have not been quantified, but
are probably of similar size. A clinically valuable system should
ideally provide a 1–2mm estimation on range, preferably using
single or few spots in the treatment plan, i.e., 108 and 106 particles
for proton and carbon therapy. Thus, reducing the MC uncertain-
ties to below 1–2mm is crucial. However, it could be a shared
effort for the PET, prompt gamma, and charged particle imaging
communities.
Keeping in mind the underlying physics and the achieved
results of the three monitoring techniques, let’s briefly sum-
marize their advantages and disadvantages. Starting with PET,
this is a well-established method proven to provide clinically
useful post-treatment information on the dose delivery. Unfor-
tunately, the response-time is intrinsically limited by the decay
time of the + emitters. However, with online PET systems that
acquire data during irradiation, a relatively quick response is
expected, making such systems particularly valuable. Geometrical
problems in planar configurations can be decreased when TOF
information is used or with innovative geometrical designs. So
far, post-treatment verification has been performed based on
entire treatment plans, so that enough statistics is collected. Pre-
treatment range measurements with one or a few single pencil-
beams are difficult, but using larger online detectors it may be
feasible in the future.
Prompt gamma detection has an important advantage with
respect to PET, because prompt gammas are produced imme-
diately when irradiating a target. This technique can thus pro-
vide real-time information, and issues with biological washout or
movement are absent. Moreover the number of prompt gamma
events produced is much larger than the number of annihila-
tion photons used in PET treatment verification. However, much
research in detector development is still needed to bring this
technique to the clinic. Single pencil-beammonitoring seems fea-
sible, although additional research is needed to confirm this. The
accuracy of MC simulations has been much improved recently,
but some crucial issues still remain to be studied, including neu-
tron backgrounds, as well as dedicated studies with heterogeneous
phantoms and patients.
Charged particle measurements can additionally provide a way
to monitor the range. Predictions of MC codes for secondary
particle production at large angles are generally not yet fully
satisfactory. Although the expected sensitivity is smaller than with
PET and prompt gammas, charged particles could for instance
provide useful additional information in combination with other
techniques, i.e., as part of a “hybrid” system. An example of
such a system is being built in the framework of the INSIDE
project (196), where a planar TOF PET system is combined with
a tracking system to provide range monitoring measurements at
the CNAO treatment facility in Pavia, Italy. More MC studies to
assess the value of this kind of hybrid systems would be very
useful, for instance it would be highly interesting to study triple
system, combining PET, prompt gamma, and charged particle
measurements.
Direct comparison studies with MC simulations are a good
way to compare the techniques. However, such studies are scarce.
Moteabbed et al. (197) performed a patient simulation study
with Geant4 comparing the PET and prompt gamma techniques
in proton treatments. They found that prompt gamma imag-
ing was potentially advantageous for certain tumor types; how-
ever, the study was based on in-room PET and moreover the
Geant4 code has significantly changed. New comparison studies
between the various techniques would therefore be timely. Since
the accuracy of each technique undoubtedly depends on treatment
site, tumor type, depth, volume, treatment plan, particle beam,
and so on, it is important that such comparison studies include
large patient groups, and present their results as quantitative as
possible.
Finally, the diversity of the literature studied here, encompass-
ing nuclear physics, MC codes, detectors, and clinical challenges,
highlights how much knowledge from different fields has been
combined in the developments of range monitoring strategies.
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In particular, the literature studied to describe the modeling of
nuclear interactions in the human body covers a time span ofmore
than 70 years. Having even omitted biological issues, it is clear
thatmodeling the underlying physics inMC codes and developing
the ultimate range verification technique requires expertise which
goes far beyond the field of medical physics alone.
6. Conclusion
This review was aimed at providing a description of the most rele-
vant aspects of the underlying physics and modeling in MC codes
used in treatment monitoring techniques based on secondary
particle detection. The complexity and variety of the underlying
physics makes an accurate description of the production of sec-
ondary particles a highly challenging andnon-trivial task.Wehave
shown how various research groups validate and apply different
MC codes to obtain their reference distributions, needed for a
comparison with data.
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